Alnylam Pharmaceuticals, Inc. - Understand $alny stock

$ALNY Market Cap: $32.85 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$2.095B

TTM

Gross Margin

85.71%

TTM

Net Earnings

-$332.3M

TTM

Current Assets

$3.355B

Q3 2024

Current Liabilities

$1.221B

Q3 2024

Current Ratio

274.89%

Q3 2024

Total Assets

$4.205B

Q3 2024

Total Liabilities

$4.173B

Q3 2024

Book Value

$32.35M

Q3 2024

Cash

$1.100B

Q3 2024

P/E

-98.88

Nov 29, 2024 EST

Free Cash Flow

$16.01M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	$1.828B	$1.037B	$844.3M	$492.9M	$219.8M	$74.91M	$89.91M	$47.16M	$41.10M	$50.60M	$47.20M	$66.70M	$82.80M	$100.0M	$100.5M	$96.20M	$50.90M	$26.90M	$5.700M	$4.300M	$200.0K	$0.00
YoY Change	76.23%	22.88%	71.31%	124.28%	193.36%	-16.69%	90.66%	14.74%	-18.77%	7.2%	-29.24%	-19.44%	-17.2%	-0.5%	4.47%	89.0%	89.22%	371.93%	32.56%	2050.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	$1.828B	$1.037B	$844.3M	$492.9M	$219.8M	$74.91M	$89.91M	$47.16M	$41.10M	$50.60M	$47.20M	$66.70M	$82.80M	$100.0M	$100.5M	$96.20M	$50.90M	$26.90M	$5.700M	$4.300M	$200.0K	$0.00
Cost Of Revenue	$268.2M	$140.2M	$115.0M	$74.19M	$25.06M	$1.802M	$0.00
Gross Profit	$1.560B	$897.2M	$729.3M	$418.7M	$194.7M	$73.11M	$89.91M
Gross Profit Margin	85.33%	86.49%	86.38%	84.95%	88.6%	97.59%	100.0%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Selling, General & Admin	$795.6M	$770.7M	$620.6M	$588.4M	$479.0M	$382.4M	$199.4M	$89.35M	$60.60M	$44.50M	$27.20M	$43.70M	$38.30M	$37.40M	$39.90M	$27.10M	$23.40M	$17.20M	$14.20M	$11.90M	$7.500M	$900.0K
YoY Change	3.24%	24.17%	5.48%	22.84%	25.28%	91.79%	123.12%	47.45%	36.18%	63.6%	-37.76%	14.1%	2.41%	-6.27%	47.23%	15.81%	36.05%	21.13%	19.33%	58.67%	733.33%
% of Gross Profit	51.0%	85.89%	85.1%	140.55%	246.04%	523.02%	221.73%
Research & Development	$1.004B	$883.0M	$792.2M	$654.8M	$655.1M	$505.4M	$390.6M	$382.4M	$276.5M	$190.2M	$113.0M	$86.57M	$99.30M	$106.4M	$108.7M	$96.88M	$120.7M	$49.30M	$35.00M	$24.60M	$13.10M	$3.300M
YoY Change	13.75%	11.47%	20.97%	-0.05%	29.62%	29.38%	2.16%	38.3%	45.33%	68.43%	30.48%	-12.82%	-6.66%	-2.16%	12.23%	-19.73%	144.83%	40.86%	42.28%	87.79%	296.97%
% of Gross Profit	64.38%	98.41%	108.62%	156.41%	336.49%	691.35%	434.46%
Depreciation & Amortization	$51.60M	$39.10M	$36.80M	$30.20M	$16.60M	$12.80M	$13.37M	$15.13M	$19.05M	$11.93M	$10.23M	$9.035M	$5.125M	$4.941M	$6.000M	$5.700M	$4.100M	$4.100M	$3.000M	$2.400M	$800.0K	$0.00
YoY Change	31.97%	6.25%	21.85%	81.93%	29.69%	-4.24%	-11.65%	-20.58%	59.74%	16.59%	13.22%	76.29%	3.72%	-17.65%	5.26%	39.02%	0.0%	36.67%	25.0%	200.0%
% of Gross Profit	3.31%	4.36%	5.05%	7.21%	8.53%	17.51%	14.87%
Operating Expenses	$1.800B	$1.654B	$1.413B	$1.243B	$1.134B	$887.8M	$590.0M	$471.7M	$337.1M	$455.5M	$140.1M	$196.2M	$137.6M	$144.1M	$108.7M	$96.88M	$144.1M	$66.40M	$49.20M	$36.50M	$20.60M	$4.200M
YoY Change	8.85%	17.05%	13.64%	9.62%	27.75%	50.47%	25.07%	39.94%	-26.0%	225.13%	-28.58%	42.6%	-4.54%	32.54%	12.23%	-32.77%	117.02%	34.96%	34.79%	77.18%	390.48%
Operating Profit	-$282.2M	-$785.1M	-$708.7M	-$828.4M	-$939.4M	-$814.7M	-$500.1M	-$424.6M	-$296.0M	-$405.0M	-$92.94M	-$129.5M	-$54.82M	-$44.07M
YoY Change	-64.06%	10.78%	-14.46%	-11.81%	15.31%	62.91%	17.78%	43.44%	-26.91%	335.73%	-28.21%	136.16%	24.39%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Interest Expense	$121.2M	$156.0M	$143.0M	$84.50M	$0.00	$0.00	$12.20M	$8.300M	$5.900M	$2.600M	$1.100M	-$3.500M	-$2.300M	-$5.300M	$500.0K	$4.300M	$13.20M	$5.100M	$600.0K	-$200.0K	$100.0K	$100.0K
YoY Change	-22.28%	9.05%	69.26%			-100.0%	46.99%	40.68%	126.92%	136.36%	-131.43%	52.17%	-56.6%	-1160.0%	-88.37%	-67.42%	158.82%	750.0%	-400.0%	-300.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	-$151.3M	-$341.9M	-$143.5M	-$27.16M	$54.18M	$54.00M	$9.214M	$14.48M	$5.935M	$4.376M	$1.022M	$12.87M	-$2.831M	$1.069M	$600.0K	-$1.900M	-$300.0K	-$300.0K	$0.00	-$200.0K	$0.00	$0.00
YoY Change	-55.74%	138.29%	428.28%	-150.13%	0.33%	486.05%	-36.36%	143.96%	35.63%	328.18%	-92.06%	-554.61%	-364.83%	78.17%	-131.58%	533.33%	0.0%		-100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Pretax Income	-$433.5M	-$1.127B	-$852.1M	-$855.6M	-$885.3M	-$760.7M	-$490.9M	-$410.1M	-$290.1M	-$400.6M	-$91.92M	-$116.6M	-$57.65M	-$43.00M	-$47.00M	-$25.50M	-$80.20M	-$34.60M	-$42.90M	-$32.70M	-$25.00M	-$4.100M
YoY Change	-61.53%	32.25%	-0.4%	-3.35%	16.38%	54.96%	19.69%	41.38%	-27.59%	335.82%	-21.16%	102.23%	34.06%	-8.51%	84.31%	-68.2%	131.79%	-19.35%	31.19%	30.8%	509.76%
Income Tax	$6.700M	$4.200M	$700.0K	$2.681M	$863.0K	$823.0K	$0.00	$0.00	$0.00	-$40.21M	-$2.695M	-$10.57M	$0.00	$514.0K	$600.0K	$700.0K	$5.200M	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$440.2M	-$1.131B	-$852.8M	-$858.3M	-$886.1M	-$761.5M	-$490.9M	-$410.1M	-$290.1M	-$360.4M	-$89.23M	-$106.0M	-$57.65M	-$43.52M	-$47.60M	-$26.20M	-$85.50M	-$34.60M	-$42.90M	-$32.70M	-$25.00M	-$4.100M
YoY Change	-61.08%	32.64%	-0.64%	-3.14%	16.37%	55.13%	19.69%	41.38%	-19.51%	303.92%	-15.84%	83.9%	32.48%	-8.58%	81.68%	-69.36%	147.11%	-19.35%	31.19%	30.8%	509.76%
Net Earnings / Revenue	-24.08%	-109.04%	-101.01%	-174.15%	-403.24%	-1016.58%	-545.95%	-869.63%	-705.77%	-712.24%	-189.04%	-158.94%	-69.62%	-43.52%	-47.36%	-27.23%	-167.98%	-128.62%	-752.63%	-760.47%	-12500.0%
Basic Earnings Per Share	-$3.52	-$9.30	-$7.20	-$7.46	-$8.11
Diluted Earnings Per Share	-$3.52	-$9.30	-$7.20	-$7.46	-$8.11	-$7.570M	-$5.418M	-$4.791M	-$3.454M	-$4.851M	-$1.448M	-$2.107M	-$1.358M	-$1.036M	-$1.144M	-$637.5K	-$2.209M	-$1.085M	-$1.959M	-$1.694M	-$1.295M	-$212.4K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Cash & Short-Term Investments	$2.439B	$2.192B	$2.436B	$1.874B	$1.536B	$1.084B	$1.691B	$626.8M	$1.081B	$696.7M	$245.9M	$122.8M	$146.4M	$233.1M	$281.4M	$430.4M	$389.9M	$217.3M	$80.00M	$46.00M	$23.20M	$15.50M
YoY Change	11.27%	-9.98%	29.94%	22.02%	41.69%	-35.87%	169.72%	-41.99%	55.09%	183.33%	100.24%	-16.12%	-37.19%	-17.16%	-34.62%	10.39%	79.43%	171.63%	73.91%	98.28%	49.68%
Cash & Equivalents	$812.7M	$866.4M	$820.0M	$496.6M	$547.2M	$420.1M	$645.4M	$193.6M	$180.9M	$75.20M	$53.20M	$51.40M	$70.20M	$74.60M	$137.5M	$191.8M	$105.2M	$128.0M	$15.80M	$20.30M	$23.20M	$15.50M
Short-Term Investments	$1.627B	$1.326B	$1.616B	$1.378B	$989.0M	$664.0M	$1.045B	$433.2M	$899.6M	$621.5M	$192.7M	$71.40M	$76.20M	$158.5M	$143.9M	$238.6M	$284.8M	$89.30M	$64.20M	$25.80M	$0.00
Other Short-Term Assets	$126.4M	$132.9M	$88.08M	$62.80M	$80.30M	$73.70M	$40.10M	$21.70M	$16.60M	$9.700M	$3.900M	$2.600M	$4.200M	$6.900M	$6.100M	$8.600M	$2.900M	$1.700M	$1.700M	$1.000M	$1.000M	$0.00
YoY Change	-4.92%	50.91%	40.25%	-21.79%	8.96%	83.79%	84.79%	30.72%	71.13%	148.72%	50.0%	-38.1%	-39.13%	13.11%	-29.07%	196.55%	70.59%	0.0%	70.0%	0.0%
Inventory	$89.15M	$129.0M	$86.36M	$75.20M	$56.30M	$24.10M
Prepaid Expenses
Receivables	$228.2M	$205.6M	$125.3M	$68.90M	$43.00M	$18.80M	$34.00M	$23.30M	$8.300M	$39.90M	$4.200M	$100.0K	$1.500M	$3.500M	$6.000M	$4.200M	$5.000M	$3.800M	$800.0K	$1.200M	$0.00
Other Receivables	$99.58M	$32.34M	$73.27M	$533.5M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$10.60M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.983B	$2.692B	$2.809B	$2.615B	$1.716B	$1.201B	$1.765B	$671.9M	$1.105B	$746.4M	$254.0M	$125.6M	$152.0M	$254.1M	$293.5M	$443.1M	$397.9M	$222.8M	$82.40M	$48.20M	$24.20M	$15.50M
YoY Change	10.79%	-4.14%	7.41%	52.39%	42.91%	-31.96%	162.64%	-39.22%	48.1%	193.86%	102.23%	-17.37%	-40.18%	-13.42%	-33.76%	11.36%	78.59%	170.39%	70.95%	99.17%	56.13%
Property, Plant & Equipment	$725.8M	$738.6M	$733.6M	$706.5M	$646.4M	$320.7M	$181.9M	$114.6M	$27.80M	$21.70M	$16.40M	$19.80M	$14.60M	$18.30M	$18.30M	$19.20M	$13.80M	$12.20M	$10.60M	$11.70M	$4.800M	$500.0K
YoY Change	-1.74%	0.68%	3.84%	9.3%	101.56%	76.31%	58.73%	312.23%	28.11%	32.32%	-17.17%	35.62%	-20.22%	0.0%	-4.69%	39.13%	13.11%	15.09%	-9.4%	143.75%	860.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments							$13.90M	$324.8M	$251.8M	$279.8M	$150.1M	$142.2M	$114.4M	$120.4M	$160.3M	$83.90M	$74.80M	$0.00
YoY Change							-95.72%	28.99%	-10.01%	86.41%	5.56%	24.3%	-4.98%	-24.89%	91.06%	12.17%
Other Assets	$121.4M	$115.5M	$101.1M	$85.80M	$32.90M	$53.40M	$34.20M	$151.6M	$1.500M	$31.70M			$800.0K	$0.00	$8.600M	$7.700M	$6.300M	$3.100M	$2.900M	$2.800M	$2.400M	$100.0K
YoY Change	5.12%	14.23%	17.83%	160.79%	-38.39%	56.14%	-77.44%	10006.67%	-95.27%					-100.0%	11.69%	22.22%	103.23%	6.9%	3.57%	16.67%	2300.0%
Total Long-Term Assets	$847.2M	$854.1M	$834.7M	$792.3M	$679.2M	$374.1M	$230.0M	$590.9M	$281.1M	$333.2M	$166.5M	$161.9M	$129.9M	$139.2M	$187.9M	$111.6M	$95.90M	$17.20M	$15.90M	$17.90M	$11.00M	$600.0K
YoY Change	-0.81%	2.32%	5.36%	16.65%	81.56%	62.65%	-61.08%	110.21%	-15.64%	100.12%	2.84%	24.63%	-6.68%	-25.92%	68.37%	16.37%	457.56%	8.18%	-11.17%	62.73%	1733.33%
Total Assets	$3.830B	$3.546B	$3.643B	$3.407B	$2.395B	$1.575B	$1.995B	$1.263B	$1.387B	$1.080B	$420.5M	$287.5M	$281.9M	$393.3M	$481.4M	$554.7M	$493.8M	$240.0M	$98.30M	$66.10M	$35.20M	$16.10M
YoY Change
Accounts Payable	$55.52M	$98.09M	$73.43M	$52.00M	$49.90M	$59.70M	$28.40M	$54.50M	$16.80M	$15.10M	$5.900M	$4.400M	$5.800M	$9.300M	$12.50M	$2.600M	$3.800M	$4.100M	$2.000M	$900.0K	$1.500M	$700.0K
YoY Change	-43.4%	33.6%	41.2%	4.21%	-16.42%	110.21%	-47.89%	224.4%	11.26%	155.93%	34.09%	-24.14%	-37.63%	-25.6%	380.77%	-31.58%	-7.32%	105.0%	122.22%	-40.0%	114.29%
Accrued Expenses	$754.5M	$587.4M	$435.7M	$392.8M	$224.9M	$112.7M	$72.20M	$42.10M	$28.80M	$23.70M	$14.20M	$11.60M	$12.30M	$11.10M	$9.800M	$9.300M	$11.70M	$4.500M	$3.900M	$3.900M	$1.400M	$2.000M
YoY Change	28.45%	34.82%	10.93%	74.66%	99.56%	56.09%	71.5%	46.18%	21.52%	66.9%	22.41%	-5.69%	10.81%	13.27%	5.38%	-20.51%	160.0%	15.38%	0.0%	178.57%	-30.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due																	$3.800M	$3.200M	$1.900M	$800.0K	$600.0K	$0.00
YoY Change																	18.75%	68.42%	137.5%	33.33%
Total Short-Term Liabilities	$967.8M	$767.9M	$695.7M	$585.3M	$352.6M	$179.5M	$144.3M	$131.7M	$62.10M	$95.30M	$53.90M	$48.30M	$81.00M	$102.0M	$110.7M	$99.50M	$83.50M	$22.90M	$18.50M	$6.600M	$3.800M	$2.700M
YoY Change	26.03%	10.38%	18.86%	66.0%	96.43%	24.39%	9.57%	112.08%	-34.84%	76.81%	11.59%	-40.37%	-20.59%	-7.86%	11.26%	19.16%	264.63%	23.78%	180.3%	73.68%	40.74%
Long-Term Debt	$1.021B	$1.017B	$675.7M	$191.3M	$0.00	$30.00M	$30.00M	$150.0M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$3.000M	$5.900M	$5.500M	$6.400M	$1.300M	$0.00
YoY Change	0.38%	50.5%	253.21%		-100.0%	0.0%	-80.0%									-100.0%	-49.15%	7.27%	-14.06%	392.31%
Other Long-Term Liabilities	$2.062B	$1.920B	$1.684B	$1.614B	$603.8M	$63.30M	$54.00M	$60.90M	$59.70M	$48.00M	$96.30M	$105.1M	$82.90M	$133.0M	$192.7M	$253.1M	$208.2M	$10.00M	$12.60M	$7.000M	$1.600M	$0.00
YoY Change	7.41%	14.02%	4.3%	167.36%	853.87%	17.22%	-11.33%	2.01%	24.38%	-50.16%	-8.37%	26.78%	-37.67%	-30.98%	-23.86%	21.57%	1982.0%	-20.63%	80.0%	337.5%
Total Long-Term Liabilities	$3.083B	$2.937B	$2.359B	$1.806B	$603.8M	$93.30M	$84.00M	$210.9M	$59.70M	$48.00M	$96.30M	$105.1M	$82.90M	$133.0M	$192.7M	$253.1M	$211.2M	$15.90M	$18.10M	$13.40M	$2.900M	$0.00
YoY Change	4.97%	24.47%	30.67%	199.04%	547.16%	11.07%	-60.17%	253.27%	24.38%	-50.16%	-8.37%	26.78%	-37.67%	-30.98%	-23.86%	19.84%	1228.3%	-12.15%	35.07%	362.07%
Total Liabilities	$4.051B	$3.705B	$3.055B	$2.391B	$956.4M	$272.8M	$228.3M	$342.6M	$121.8M	$143.3M	$150.2M	$153.5M	$163.9M	$235.0M	$303.4M	$352.6M	$294.6M	$38.80M	$36.60M	$20.00M	$6.700M	$2.700M
YoY Change	9.34%	21.26%	27.79%	149.98%	250.59%	19.49%	-33.36%	181.28%	-15.0%	-4.59%	-2.15%	-6.35%	-30.26%	-22.54%	-13.95%	19.69%	659.28%	6.01%	83.0%	198.51%	148.15%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	124.9M shares	121.7M shares	118.5M shares	115.0M shares	109.3M shares
Diluted Shares Outstanding	124.9M shares	121.7M shares	118.5M shares	115.0M shares	109.3M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $32.854 Billion

About ALNYLAM PHARMACEUTICALS, INC.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,100 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.

Industry: Pharmaceutical Preparations Peers: BIOGEN INC. Biohaven Pharmaceutical Holding Co Ltd. BIOMARIN PHARMACEUTICAL INC INCYTE CORP Moderna, Inc. NEUROCRINE BIOSCIENCES INC REGENERON PHARMACEUTICALS, INC. Seagen Inc. VERTEX PHARMACEUTICALS INC / MA